LeonaBio, Inc. logo

LeonaBio, Inc.

LONA

NASDAQHealthcareBiotechnology

Latest quote

$7.51

−$0.145 · -1.89%

Aug 24, 10:25 AM ET

LONA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

45

Fair Value

Momentum

72

Gaining

Sentiment

63

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Mark J. Litton
Listed since
Sep 18, 2020
Employees
19

Market position

Volume
6.55K
0.17× average
Average volume
38.43K
Average daily volume
Market cap
29.74M USD
Beta
2.04
Market reference 1

LONA peers

Continue in GoAI

Research LONA

research.disclaimer